» Articles » PMID: 35300332

Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia

Overview
Journal Front Immunol
Date 2022 Mar 18
PMID 35300332
Authors
Affiliations
Soon will be listed here.
Abstract

Primary Membranous Nephropathy (PMN) is the most frequent cause of nephrotic syndrome in adults. If untreated, PMN can lead to end-stage renal disease; moreover, affected patients are at increased risk of complications typical of nephrotic syndrome such as fluid overload, deep vein thrombosis and infection. The association of PMN with and the identification in around 70% of cases of circulating autoantibodies, mainly directed towards the phospholipase A2 receptor, supports the autoimmune nature of the disease. In patients not achieving spontaneous remission or in the ones with deteriorating kidney function and severe nephrotic syndrome, immunosuppression is required to increase the chances of achieving remission. The aim of this review is to discuss the evidence base for the different immunosuppressive regimens used for PMN in studies published so far; the manuscript also includes a section where the authors propose, based upon current evidence, their recommendations regarding immunosuppression in the disease, while highlighting the still significant knowledge gaps and uncertainties.

Citing Articles

Focal segmental glomerulosclerosis (FSGS) in pregnancy: The case of a 27-year-old woman with nephrotic syndrome at 22 weeks of gestation.

Wang L, Viswanathan S, Fischer E, Bose B SAGE Open Med Case Rep. 2024; 12:2050313X241300658.

PMID: 39544502 PMC: 11561983. DOI: 10.1177/2050313X241300658.


A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy.

Wang Y, Ma X, Yang X, Bai S, Zang X, Liao L Ren Fail. 2024; 46(2):2409353.

PMID: 39351796 PMC: 11445897. DOI: 10.1080/0886022X.2024.2409353.


Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.

Duan S, Chen S, Chen C, Lu F, Pan Y, Lu Y Ren Fail. 2024; 46(1):2359024.

PMID: 38832491 PMC: 11151798. DOI: 10.1080/0886022X.2024.2359024.


Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases.

Perico L, Casiraghi F, Sonego F, Todeschini M, Corna D, Cerullo D Front Immunol. 2024; 15:1335998.

PMID: 38469301 PMC: 10926275. DOI: 10.3389/fimmu.2024.1335998.


Proteomic analysis of glomeruli, tubules and renal interstitium in idiopathic membranous nephropathy (IMN): A statistically observational study.

Lu C, Luo Z, Tang D, Zheng F, Li S, Liu S Medicine (Baltimore). 2023; 102(50):e36476.

PMID: 38115247 PMC: 10727647. DOI: 10.1097/MD.0000000000036476.


References
1.
Branten A, Reichert L, Koene R, Wetzels J . Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM. 1998; 91(5):359-66. DOI: 10.1093/qjmed/91.5.359. View

2.
Rostoker G, Belghiti D, Ben Maadi A, Remy P, Lang P, Weil B . Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron. 1993; 63(3):335-41. DOI: 10.1159/000187219. View

3.
Sethi S, Debiec H, Madden B, Vivarelli M, Charlesworth M, Ravindran A . Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int. 2020; 98(5):1253-1264. DOI: 10.1016/j.kint.2020.05.030. View

4.
Muller-Deile J, Schiffer L, Hiss M, Haller H, Schiffer M . A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest. 2015; 45(12):1260-9. DOI: 10.1111/eci.12545. View

5.
Liang Q, Li H, Xie X, Qu F, Li X, Chen J . The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail. 2017; 39(1):512-518. PMC: 6014322. DOI: 10.1080/0886022X.2017.1325371. View